[Treatment of ventricular arrhythmias with mexiletine].
The development of new antiarrhythmic drugs allows to a certain extent the performance of a differential therapy and prophylaxis. This also concerns the lidocaine-like substance mexiletine, which according to Vaughan-Williams is to be classified into class I B of the antiarrhythmic drugs with direct membrane effect. It is effective in disturbances of the ventricular rhythm also in oral therapy, which in most cases are more life-endangering than the supraventricular ones. In own examination in 21 of 26 patients a complete or far-reaching suppression of accumulated extrasystoles and particularly of ventricular tachycardias could be achieved by an oral long-term therapy with 600--800 mg mexiletine. In the acute experiment short-term infusions were not effective in patients with ventricular tachycardias, since apparently no sufficient plasma level was obtained, wherefore also a following permanent drop infusion is recommended. The rate of side-effects was insignificant and in no case led to a withdrawal of the therapy.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001682:Biological Availability; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008801:Mexiletine / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D008875:Middle Aged; D011437:Propylamines / Q000627:therapeutic use*; D013610:Tachycardia / Q000517:prevention & control
D011437:Propylamines; D008801:Mexiletine
Zur Behandlung ventrikulärer Rhythmusstörungen mit Mexiletin.